DFCI Gynecological Oncology Data Access Committee

Dr Erica M Holdmore
ericah@ds.dfci.harvard.edu

Request Access

Dataset ID	Description	Technology	Samples
EGAD50000001711	This is a Phase II clinical trial. This research study is studying a combination of targeted therapies as a possible treatment for estrogen-receptor positive (ER+) endometrial cancer and low-grade serous ovarian cancer. The drugs involved in this study are: - Abemaciclib (also known as Verzenio™) - Letrozole (also known as Femara®) - Metformin (also known as Glucophage®) - Zotatifin (also known as eFT226) - Gedatolisib (also known as PF-05212384)	Illumina NovaSeq 6000	15